REFERENCES

1. Marrero JA, Kulik LM, Sirlin CB, Zhu AX, Finn RS, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 2018;68:723-50.

2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.

3. Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004;40:993-9.

4. Lee SD, Yu ML, Cheng PN, Lai MY, Chao YC, et al. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan. J Viral Hepat 2005;12:283-91.

5. Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, et al; Group H-CT. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-44.

6. Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, et al; Group H-CT. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology 2011;140:840-9.

7. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.

8. Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370:222-32.

9. Lawitz E, Poordad FF, Pang PS, Hyland RH, Ding X, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014;383:515-23.

10. Muir AJ, Poordad F, Lalezari J, Everson G, Dore GJ, et al. Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis. JAMA 2015;313:1736-44.

11. Lawitz E, Makara M, Akarca US, Thuluvath PJ, Preotescu LL, et al. Efficacy and safety of ombitasvir, paritaprevir, and ritonavir in an open-label study of patients with genotype 1b chronic hepatitis C virus infection with and without cirrhosis. Gastroenterology 2015;149:971-80.e1.

12. Kwon JH, Yoo SH, Nam SW, Kim HY, Kim CW, et al. Clinical outcomes after the introduction of direct antiviral agents for patients infected with genotype 1b hepatitis C virus depending on the regimens: A multicenter study in Korea. J Med Virol 2019;91:1104-11.

13. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26.

14. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.

15. Masuzaki R, Tateishi R, Yoshida H, Yoshida H, Sato S, et al. Risk assessment of hepatocellular carcinoma in chronic hepatitis C patients by transient elastography. J Clin Gastroenterol 2008;42:839-43.

16. Goodgame B, Shaheen NJ, Galanko J, El-Serag HB. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol 2003;98:2535-42.

17. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, et al. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology 2017;153:996-1005.e1.

18. Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, et al; Rete Sicilia Selezione Terapia HCV. Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 2018;155:411-21.e4.

19. Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol 2018;69:345-52.

20. Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, et al; Ochanomizu Liver Conference Study G. Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C. J Hepatol 2017;67:933-9.

21. Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, et al; Group ACC. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology 2018;155:1436-50.e6.

22. Yoo SH, Kwon JH, Nam SW, Kim HY, Kim CW, et al. Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: comparison with pegylated interferon-based therapy in chronic hepatitis C patients. J Viral Hepat 2018;25:1189-96.

23. Singer AW, Reddy KR, Telep LE, Osinusi AO, Brainard DM, et al. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study. Aliment Pharmacol Ther 2018;47:1278-87.

24. Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, et al; French ACOHc. Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study. Lancet 2019;393:1453-64.

25. Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, et al. Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study. Hepatol Int 2019;13:293-301.

26. Poon RT, Fan ST, Lo CM, Liu CL, Wong J. Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 2002;235:373-82.

27. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg 2015;261:947-55.

28. Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC, et al. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): a meta-regression approach. J Hepatol 2010;52:889-94.

29. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228-32.

30. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963-7.

31. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, et al. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376-82.

32. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, et al; Force HCCIT. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006;44:1543-54.

33. ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.

34. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavo MR, et al; Rete Sicilia Selezione Terapia HCV. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017;46:688-95.

35. Nishibatake Kinoshita M, Minami T, Tateishi R, Wake T, Nakagomi R, et al. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: comparison with interferon-based therapy. J Hepatol 2019;70:78-86.

36. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol 2017;67:1204-12.

37. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, et al. Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology 2019;156:1683-92.e1.

38. Kanda T, Lau GKK, Wei L, Moriyama M, Yu ML, et al. APASL HCV guidelines of virus-eradicated patients by DAA on how to monitor HCC occurrence and HBV reactivation. Hepatol Int 2019;13:649-61.

39. Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, et al. Cure with Interferon Free DAA is Associated with Increased Survival in Patients with HCV related HCC from both East and West. Hepatology 2019; doi: 10.1002/hep.30988.

40. Cheung MCM, Walker AJ, Hudson BE, Verma S, McLauchlan J, et al; UK HCVR. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 2016;65:741-7.

41. Hanafy AS, Bassiony MA, Basha MAA. Management of HCV-related decompensated cirrhosis with direct-acting antiviral agents: who should be treated? Hepatol Int 2019;13:165-72.

42. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2018;1:25-32.